SUNPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.2
| Stock Code | SUNPHARMA | Market Cap | 4,08,679 Cr. | Current Price | 1,704 ₹ | High / Low | 1,851 ₹ |
| Stock P/E | 93.7 | Book Value | 99.2 ₹ | Dividend Yield | 0.94 % | ROCE | 16.8 % |
| ROE | 17.8 % | Face Value | 1.00 ₹ | DMA 50 | 1,697 ₹ | DMA 200 | 1,697 ₹ |
| Chg in FII Hold | -0.43 % | Chg in DII Hold | 0.60 % | PAT Qtr | 872 Cr. | PAT Prev Qtr | 564 Cr. |
| RSI | 55.5 | MACD | -21.7 | Volume | 46,48,701 | Avg Vol 1Wk | 47,98,138 |
| Low price | 1,547 ₹ | High price | 1,851 ₹ | PEG Ratio | 1.28 | Debt to equity | 0.56 |
| 52w Index | 51.6 % | Qtr Profit Var | -24.6 % | EPS | 16.7 ₹ | Industry PE | 29.1 |
📊 Analysis: SUNPHARMA shows limited intraday potential today. Current price (1,704 ₹) is aligned with both 50 DMA and 200 DMA (1,697 ₹), suggesting neutral trend support. RSI at 55.5 indicates balanced momentum, neither overbought nor oversold. MACD at -21.7 is negative, pointing to bearish bias. Volume (46.4 lakh) is slightly below the 1-week average (47.9 lakh), reflecting moderate participation. The stock is trading at 51.6% of its 52-week high, showing mid-range positioning.
💰 Optimal Buy Price: 1,695–1,700 ₹ (near DMA support).
📈 Profit-Taking Exit Levels: 1,720–1,735 ₹ (short-term resistance zone).
🛑 Stop-Loss / Loss Protection: 1,685 ₹ (below DMA support).
⏱️ If Already Holding: Exit intraday if price fails to sustain above 1,705 ₹ with weakening momentum or if MACD continues negative. Book profits if price approaches 1,720–1,735 ₹ but volume remains weak or momentum indicators flatten.
✅ Positive
- Price holding near DMA levels, offering technical support.
- ROE at 17.8% and ROCE at 16.8% indicate strong efficiency.
- DII holdings increased (+0.60%).
- EPS at 16.7 ₹ reflects earnings strength.
⚠️ Limitation
- High P/E ratio (93.7) compared to industry average (29.1).
- MACD negative, signaling bearish momentum.
- Volume slightly below average, limiting intraday volatility.
📉 Company Negative News
- Quarterly PAT declined (872 Cr vs 564 Cr previously, -24.6% variation).
- FII holdings decreased (-0.43%).
📈 Company Positive News
- Dividend yield at 0.94% adds investor appeal.
- Strong market cap (4,08,679 Cr.) ensures stability.
- Debt-to-equity ratio at 0.56 is manageable.
🏭 Industry
- Industry PE at 29.1, much lower than SUNPHARMA’s P/E, suggesting overvaluation.
- Pharmaceutical sector remains defensive with steady demand.
🔎 Conclusion
SUNPHARMA is a cautious candidate for intraday trading today. The stock trades near DMA support but faces bearish MACD signals and weak volume. A buy zone near 1,695–1,700 ₹ with exit around 1,720–1,735 ₹ is possible, but strict stop-loss at 1,685 ₹ is essential. Momentum indicators suggest limited upside, so traders should remain conservative.